CNJ-016 (Cangene Corporation)
Welcome to the PulseAid listing for the CNJ-016 drug offered from Cangene Corporation. This Human Immunoglobulin G [EPC],Passively Acquired Immunity [PE],Virus Neutralization [MoA],Virus-specific Hyperimmune Globulins [Chemical/Ingredient],Immunoglobulins [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Cangene Corporation |
| NON-PROPRIETARY NAME: | Vaccinia Immune Globulin (Human) |
| SUBSTANCE NAME: | HUMAN VACCINIA VIRUS IMMUNE GLOBULIN |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Human Immunoglobulin G [EPC],Passively Acquired Immunity [PE],Virus Neutralization [MoA],Virus-specific Hyperimmune Globulins [Chemical/Ingredient],Immunoglobulins [Chemical/Ingredient] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2005-05-02 |
| END MARKETING DATE: | 0000-00-00 |
CNJ-016 HUMAN PRESCRIPTION DRUG Details:
| Item Description | CNJ-016 from Cangene Corporation |
| LABELER NAME: | Cangene Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 1([iU]/mL) |
| START MARKETING DATE: | 2005-05-02 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 60492-0173_0e0c62af-eeab-4de9-9514-9210ad25c3a1 |
| PRODUCT NDC: | 60492-0173 |
| APPLICATION NUMBER: | BLA125109 |
Other HUMAN VACCINIA VIRUS IMMUNE GLOBULIN Pharmaceutical Manufacturers / Labelers:
